News Center
——
News Center
BroadenBio’s Pre-clinical Project on Class 1 New Drug Approved by Beijing Municipal Science and Technology Commission
Time of issue：
2021-04-23
Author:
BroadenBio
Origin:
BroadenBio
The project of "Pre-clinical Studies on Class 1 Investigational New Drug BB168 against Liver Cancer" of BroadenBio Co., Ltd. was approved by the Beijing Municipal Science and Technology Commission in the first quarter of 2021, and received 3.9 million (CNY) of financial support.
previous page
address：
A1-602, 88 Kechuang 6th Street, BDA, Beijing 100176
phone：
Copyright ©2019 BroadenBio